Adhera Therapeutics, Inc. Announces Resignation of Eric Teague as Chief Financial Officer, Effective March 22, 2019
March 15, 2019 at 05:00 pm EDT
Share
On March 11, 2019, Eric Teague, the Chief Financial Officer of Adhera Therapeutics, Inc., submitted his resignation as the Chief Financial Officer of the Company and from any other positions (whether as an officer, director or otherwise) that he may hold with the Company or any of its subsidiaries, effective at the close of business on March 22, 2019. Mr. Teague resigned to pursue other business and personal opportunities. The Company has commenced a search to replace Mr. Teague, and it expects to appoint a successor within the coming weeks. The Company anticipates that Mr. Teague will be available to assist in the transition of his ongoing activities on behalf of the Company to his successor following the effective date of his resignation.
Adhera Therapeutics, Inc. is a specialty biotech company. The Company is focused on the drug development and commercialization of small molecule drugs to treat Parkinson's disease (PD) and Type 1 diabetes. The Company's advanced development programs are MLR-1019, a small molecule drug candidate being developed for PD, and MLR-1023, being developed to treat Type 1 diabetes. MLR-1019 is a highly selective dopamine re-uptake inhibitor for treating the dyskinesias associated with chronic dopamine precursor levodopa (L-DOPA) treatment in PD patients. MLR-1019 is a highly selective dopamine reuptake transporter (DAT) inhibitor used for the treatment of type 1 diabetes, non-alcoholic steatohepatitis, and pulmonary inflammation. It utilizes a virtual drug development model, where contract research organizations (CROs) are employed to undertake certain drug discovery and development services on the Companyâs behalf and under its direct supervision.
ADHERA THERAPEUTICS, INC. 
